Pfizer Q4 2025: Strong Performance Despite COVID Decline

Pfizer beats Q4 estimates with $17.6B revenue as legacy drugs offset COVID sales drop. Obesity drug shows 12.3% weight loss. 2026 guidance reaffirmed.